Asthma is not classified as an immunocompromised condition. Having asthma does not mean your immune system is weakened in the way that HIV, organ transplants, or chemotherapy weaken it. However, asthma does change how your airways defend against infections, and certain asthma medications can suppress parts of your immune response. The distinction matters for vaccines, infection risk, and how you think about your overall health.
Why Asthma Is Not Immunocompromised
The CDC lists asthma (moderate to severe) as a chronic lung disease that increases risk for severe illness from infections like COVID-19. But it places asthma in a separate category from “immunocompromised condition or weakened immune system,” which includes people on chemotherapy, organ transplant recipients, those with primary immunodeficiency, and people taking long-term corticosteroids. In other words, asthma puts you at higher risk for respiratory complications, but through a different mechanism than true immune suppression.
An immunocompromised person has a broadly weakened ability to fight infections throughout their body. Asthma doesn’t do that. Your body still produces antibodies normally, your white blood cells still function, and vaccines still generate a robust immune response. What asthma does affect is more localized: the structural and chemical defenses in your airways.
How Asthma Changes Your Airway Defenses
Your airways are lined with a layer of tightly connected cells that act as a physical wall against viruses, bacteria, and allergens. In asthma, this barrier is disrupted. The connections between cells loosen, ciliated cells (the ones that sweep mucus and debris out of your lungs) detach, and the lining becomes more permeable. Researchers have found that asthmatic airways show reduced levels of a key adhesion protein called E-cadherin, which normally holds these cells together. The result is that pathogens can penetrate deeper into the airway tissue more easily.
Beyond the physical barrier, asthma shifts the immune balance in your airways. The type of inflammation that dominates in most asthma (called Th2 inflammation) produces signals that can interfere with your body’s antiviral defenses. Specifically, the inflammatory molecules involved in allergic asthma suppress the production of certain interferons, proteins your cells release to alert neighboring cells to a viral invasion. When interferon signaling is impaired, your airway cells are slower to mount an effective defense against viruses like rhinovirus, the most common trigger of asthma flare-ups. This isn’t the same as being immunocompromised. It’s a localized vulnerability in the lungs, not a system-wide immune deficiency.
The Medication Factor
This is where the line between asthma and immunosuppression can blur. Corticosteroids, the backbone of asthma treatment, work by dampening inflammation. At standard inhaled doses, they act locally in the lungs and have not been shown to suppress cell-mediated immunity, the branch of the immune system responsible for fighting infections. Prolonged use of low-dose inhaled corticosteroids does not appear to affect immune function in a clinically meaningful way.
High-dose inhaled corticosteroids are a different story. One commonly prescribed inhaled steroid, fluticasone, can suppress the body’s hormonal stress response at higher doses, with systemic effects that begin to resemble those of oral steroids. This suppression is dose-dependent, meaning the higher you go, the more your whole body feels the effects rather than just your lungs.
Oral corticosteroids like prednisone clearly cross into immunosuppressive territory. The CDC’s Advisory Committee on Immunization Practices considers a dose of 20 mg per day of prednisone (or 2 mg per kilogram of body weight in children) taken for two weeks or longer to be sufficiently immunosuppressive that live vaccines should be delayed for at least three months after stopping. If you take frequent or prolonged courses of oral steroids for severe asthma, you may temporarily meet the clinical definition of immunocompromised during and shortly after treatment.
Biologics and Infection Risk
People with severe asthma increasingly use biologic therapies that target specific immune pathways. Because these drugs intentionally block parts of the immune system, there’s a reasonable question about whether they increase infection risk. Analysis of the World Health Organization’s global adverse event database found that infections were one of the most commonly reported categories of side effects for asthma biologics. A notable signal involved herpes zoster (shingles): reports of shingles were roughly two to four times more frequent with omalizumab and benralizumab compared to other drugs in the database. A small percentage of patients on dupilumab, mepolizumab, and benralizumab also developed shingles, and this risk is already noted in the prescribing information for mepolizumab.
These signals come from spontaneous reports rather than controlled trials, so they indicate a possible association rather than a confirmed rate. Still, the pattern suggests that targeting specific immune pathways in severe asthma may modestly increase susceptibility to certain opportunistic infections, particularly reactivation of dormant viruses.
Asthma, COVID-19, and Infection Outcomes
One counterintuitive finding complicates the picture. A large meta-analysis of COVID-19 outcomes in Spain found that asthma was associated with a 22% lower risk of death from COVID-19 compared to patients without asthma. Among hospitalized patients, the protective effect was even stronger. This was most pronounced in patients over 60, where asthma was associated with a 27% reduction in mortality risk.
The reasons aren’t fully settled, but several explanations have been proposed. People with asthma may have been more cautious about exposure, more likely to already be on inhaled corticosteroids (which may have had a protective effect in the lungs), or may have had immune profiles that partially dampened the dangerous overreaction that drives severe COVID-19. Whatever the cause, this data reinforces that asthma does not behave like an immunocompromised condition when it comes to fighting systemic infections.
What This Means for Vaccines and Prevention
Because asthma is not an immunocompromising condition, standard vaccines work normally for most people with asthma. Your body generates a full antibody response, and you don’t need extra doses the way transplant recipients or people on chemotherapy do. The one exception is if you’re on high-dose oral corticosteroids: live vaccines (like the nasal flu spray or the shingles vaccine Zostavax) should be postponed until at least three months after finishing a course of 20 mg or more of prednisone daily lasting two or more weeks.
Asthma does, however, earn you a recommendation for pneumococcal vaccination. The Advisory Committee on Immunization Practices added adults with asthma to the high-risk category for pneumococcal vaccination after research showed a twofold increase in invasive pneumococcal disease among asthmatics. The annual incidence of invasive pneumococcal disease per 10,000 people was 1.2 for healthy individuals, 2.3 for low-risk asthmatics, and 4.2 for high-risk asthmatics. This recommendation is based on the increased vulnerability of asthmatic airways, not on immune suppression.
The practical takeaway: asthma makes your lungs more vulnerable to respiratory infections and their complications, but it does not weaken your immune system the way conditions formally classified as immunocompromising do. The exception is medication-driven. If your treatment plan includes frequent oral steroids or high-dose inhaled steroids, the drugs themselves may temporarily suppress immune function in ways that matter for vaccine timing and infection risk.